Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAP4K4 | O95819 | 3/20 | 0.51 |
| ▸ | HRH4 | Q9H3N8 | 1/20 | 0.50 |
| ▸ | LRRK2 | Q5S007 | 1/20 | 0.45 |
| ▸ | ADORA3 | P0DMS8 | 6/20 | 0.39 |
| ▸ | ADORA1 | P30542 | 4/20 | 0.39 |
| ▸ | ADORA2A | P29274 | 3/20 | 0.39 |
| ▸ | ADORA2B | P29275 | 3/20 | 0.39 |
| ▸ | BTK | Q06187 | 1/20 | 0.39 |
| ▸ | PDGFRB | P09619 | 1/20 | 0.38 |
| ▸ | CDK1 | P06493 | 3/20 | 0.38 |
| ▸ | CCNB1 | P14635 | 3/20 | 0.38 |
| ▸ | CCNA2 | P20248 | 3/20 | 0.38 |
| ▸ | CDK2 | P24941 | 3/20 | 0.38 |
| ▸ | CCNA1 | P78396 | 3/20 | 0.38 |
| ▸ | PIN1 | Q13526 | 2/20 | 0.38 |
| ▸ | CCNB2 | O95067 | 1/20 | 0.38 |
| ▸ | MAPK3 | P27361 | 1/20 | 0.38 |
| ▸ | CLK1 | P49759 | 1/20 | 0.38 |
| ▸ | CDK5 | Q00535 | 1/20 | 0.38 |
| ▸ | CCNB3 | Q8WWL7 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30834277 | 1.00 | MAP4K4 (0.51) | MAP4K4HRH4LRRK2ADORA3ADORA1 | |
| SCHEMBL27201417 | 0.82 | MAP4K4 (0.52) | MAP4K4HRH4LRRK2BTKPIK3CA | |
| SCHEMBL30885255 | 0.79 | MAP4K4 (0.53) | MAP4K4HRH4LRRK2ADORA1ADORA2A | |
| SCHEMBL27201579 | 0.79 | MAP4K4 (0.53) | MAP4K4HRH4LRRK2ADORA1ADORA2A | |
| SCHEMBL27201481 | 0.77 | HRH4 (0.53) | MAP4K4HRH4LRRK2BTK | |
| SCHEMBL30885318 | 0.77 | HRH4 (0.53) | MAP4K4HRH4LRRK2BTK | |
| SCHEMBL27201635 | 0.77 | MAP4K4 (0.51) | MAP4K4HRH4LRRK2ADORA1ADORA2A | |
| SCHEMBL30885232 | 0.77 | MAP4K4 (0.51) | MAP4K4HRH4LRRK2ADORA1ADORA2A | |
| SCHEMBL27201474 | 0.76 | HRH4 (0.51) | MAP4K4HRH4LRRK2BTK | |
| SCHEMBL27201410 | 0.76 | MAP4K4 (0.53) | MAP4K4HRH4LRRK2CDK2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240132464-A1 | HETEROCYCLIC COMPOUNDS AS E3 LIGASE INHIBITORS | ACCUTAR BIOTECHNOLOGY INC. (US) | 2024-04-25 | — | — | US | claimed |
| US-20240132464-A1 | HETEROCYCLIC COMPOUNDS AS E3 LIGASE INHIBITORS | ACCUTAR BIOTECHNOLOGY INC. (US) | 2024-04-25 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240132464-A1 | HETEROCYCLIC COMPOUNDS AS E3 LIGASE INHIBITORS | GID4, MDM2, XIAP | MAP4K4 1878/4885HRH4 4074/4885LRRK2 209/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.